MedTrace Logo

An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery

NCT01139866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2022-06-15

No results posted yet for this study

Summary

This is an extension to a previous research trial testing SABER™-Bupivacaine (an experimental pain-relieving medication). The purpose of this extension trial is to assess whether treatment with SABER™-Bupivacaine or SABER™-Placebo has had any effect on healing of the participant's shoulder, wound, or the skin near their scar. This trial will also assess safety (side effects).

Conditions

Sponsors & Collaborators

  • Nycomed

    collaborator INDUSTRY

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Durect

    lead INDUSTRY

Principal Investigators

  • Dmitri Lissin, MD · Durect

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01139866 on ClinicalTrials.gov